Document ID: chunk:federal_register_of_legislation:F2022L00258:reg:9:p2
Version: federal_register_of_legislation:F2022L00258
Segment Type: reg
Provision Reference: reg 9 (pt 2/6)
Character Range: 7250–10189

Schedule 1 – Dictionary.
(13)      having gout or hyperuricaemia at the time of the clinical onset of hypertension;
Note: hyperuricaemia is defined in the Schedule 1 – Dictionary.
(14)      taking a drug specified in the Schedule 2 - Drugs of this Instrument, where that drug cannot be ceased or substituted, for a continuous period of at least the 28 days before the clinical onset of hypertension;
(15)      taking a drug from the Specified List 1 of drugs at the time of the clinical onset of hypertension;
Note: Specified List 1 of drugs is defined in the Schedule 1 - Dictionary.
(16)      having glucocorticoid therapy as specified before the clinical onset of hypertension, and if the glucocorticoid therapy as specified has ceased or decreased before the clinical onset of hypertension, then that onset occurred within 30 days of cessation or reduction of therapy;
Note: glucocorticoid therapy as specified is defined in the Schedule 1 - Dictionary.
(17)      taking medroxyprogesterone acetate or megestrol acetate for a malignant disease or human immunodeficiency virus infection:
(a)          for at least 28 days before the clinical onset of hypertension; and
(b)          if treatment has ceased before the clinical onset of hypertension, then that onset occurred within 30 days of cessation;
(18)      inability to undertake any physical activity greater than 3 METs for at least the 1 year before the clinical onset of hypertension;
Note: MET is defined in the Schedule 1 - Dictionary.
(19)      being exposed to arsenic as specified before the clinical onset of hypertension;
Note: being exposed to arsenic as specified is defined in the Schedule 1 - Dictionary.
(20)      undergoing a course of therapeutic radiation for cancer, where the whole body was in the field of radiation, at least 1 year before the clinical onset of hypertension;
(21)      having received a cumulative equivalent dose of at least 0.5 sievert of ionising radiation to the whole body at least 1 year before the clinical onset of hypertension;
Note: cumulative equivalent dose is defined in the Schedule 1 - Dictionary.
(22)      inhaling, ingesting or having cutaneous contact with the phenoxy acid herbicides 2,4-dichlorophenoxyacetic acid (2,4-D) or 2,4,5-trichlorophenoxyacetic acid (2,4,5-T):
(a)          for a cumulative period of at least 1,000 hours within a consecutive period of 10 years, before the clinical onset of hypertension; and
(b)          where the first exposure occurred at least 5 years before the clinical onset of hypertension; and
if that exposure has ceased before the clinical onset of hypertension, then that onset occurred within 25 years of cessation;
(23)      inhaling, ingesting or having cutaneous contact with a chemical agent contaminated by 2,3,7,8-tetrachlorodibenzo-para-dioxin (TCDD):
(a)          for a cumulative period of at least 1,000 hours within a consecutive period of 10 years, before the clinical